Abstract Number: 1509 • ACR Convergence 2025
Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Background/Purpose: Past reports have shown that serositis is a risk factor for organ damage in patients with SLE. However, the distinct clinical features of newly…Abstract Number: 2071 • ACR Convergence 2025
Impact of Diagnostic Delay on Disease Activity and Cumulative Damage in Patients with Idiopathic Inflammatory Myopathies in a Third-level Hospital in Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare and heterogeneous group of autoimmune diseases marked by inflammation of muscle tissue and extramuscular manifestations. Their atypical…Abstract Number: 2309 • ACR Convergence 2025
Lifestyle behaviours and disease activity in patients with psoriatic arthritis: the Dutch south west psoriatic arthritis study
Background/Purpose: Comprehensive assessment of multiple lifestyle behaviours and disease activity outcomes in psoriatic arthritis (PsA) is scarce. We aim to investigate lifestyle behaviours in patients…Abstract Number: 2626 • ACR Convergence 2025
Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo: Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07)
Background/Purpose: Increased pain and decreased function are hallmarks of knee OA progression. Lorecivivint (LOR), an intra-articular CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways,…Abstract Number: 0302 • ACR Convergence 2025
Urine Kynurenine Pathway Biomarkers Correlate with Disease Activity and Damage Core Set Measures in JDM
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune vasculopathy affecting muscle, skin, and vasculature. Core set measures (CSM) assess disease activity and damage, and guide treatment.…Abstract Number: 0487 • ACR Convergence 2025
Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan
Background/Purpose: The efficacy and safety of sarilumab (SAR) and methotrexate (MTX) in patients (pts) in Japan with moderate-to-severely active rheumatoid arthritis (RA) and inadequate response…Abstract Number: 0892 • ACR Convergence 2025
Relapse and Immune Dysregulation in Giant Cell Arteritis Are Linked to Mosaic Loss of the Y Chromosome
Background/Purpose: Mosaic loss of the Y chromosome (mLOY) is the most common acquired somatic mutation. Epidemiological studies have linked mLOY to malignancies, as well as…Abstract Number: 1207 • ACR Convergence 2025
Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by cutaneous manifestations and proximal muscle inflammation.1,2 Notably, the clinical course of muscular and cutaneous disease…Abstract Number: 1409 • ACR Convergence 2025
The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)
Background/Purpose: The burden of comorbidities in Axial Spondyloarthritis (axSpA) is increasingly recognised and contributes to the concept of difficult-to-treat axSpA (D2T-axSpA). The need to assess…Abstract Number: 1531 • ACR Convergence 2025
Achieving Remission and Low Disease Activity with Belimumab Versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
Background/Purpose: An integrated post hoc analysis of five Phase 3 trials in adults with SLE showed greater benefit of belimumab (BEL) than placebo (PBO), plus…Abstract Number: 2075 • ACR Convergence 2025
Ferritin trends differentiate anti-MDA5 Dermatomyositis from anti-Jo1 Antisynthetase Syndrome
Background/Purpose: Serum ferritin (FERR) is a recognized marker of immune activation and a key laboratory feature of anti-MDA5 Dermatomyositis (DM). It has been increasingly studied…Abstract Number: 2317 • ACR Convergence 2025
Cardiovascular Risk and Psoriatic Arthritis Features: Dactylitis may Predict Cardiovascular Events
Background/Purpose: Patients with PsA have an elevated risk of cardiovascular (CV) disease. We assessed whether specific PsA features may predict CV events among PsA patients.Methods:…Abstract Number: 2640 • ACR Convergence 2025
Effectiveness of Biological and Target-Synthetic Treatment in Patients with Rheumatoid Arthritis and Kidney Dysfunction: A Large Prospective Registry Study
Background/Purpose: Kidney dysfunction is common in patients with rheumatoid arthritis (RA). However, there has been limited and conflicting evidence on the effectiveness of biologic and…Abstract Number: 0380 • ACR Convergence 2025
Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients
Background/Purpose: Fatigue is a highly prevalent (40%-70%)1 comorbidity in rheumatoid arthritis (RA) patients, and residual fatigue has been described in a significant proportion of patients…Abstract Number: 0488 • ACR Convergence 2025
Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH
Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients (pts) with rheumatoid arthritis (RA) in Europe. In…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 112
- Next Page »
